Writing Group Disclosures
| Writing Group Member |
Employment | Research Grant | Other Research Support |
Speakers’ Bureau/ Honoraria |
Expert Witness |
Ownership Interest |
Consultant/ Advisory Board |
Other |
|---|---|---|---|---|---|---|---|---|
| Sharonne N. Hayes | Mayo Clinic | None | None | None | None | None | None | None |
| Esther S.H. Kim | Vanderbilt University | None | None | None | None | None | None | None |
| Jacqueline Saw | Vancouver General Hospital Canada | Abbott Vascular (Canadian SCAD Study)†; Boston Scientific (Canadian Watchman Registry, ASAP- TOO study)† | None | Boston Scientific* | None | None | Abbott Vascular†; Boston Scientific† | None |
| David Adlam | University of Leicester, UK Glenfield Hospital United Kingdom | Abbott Vascular (support research relating to optical coherence tomography imaging)*; AstraZeneca (study of the role of antiplatelet agents for the prevention of cancer metastasis)*; BeatSCAD charity (spontaneous coronary artery dissection)*; British Heart Foundation (spontaneous coronary dissection)*; NIHR rare diseases TRC (rare coronary phenotypes including spontaneous coronary artery dissection)*; Leicester NIHR Biomedical Research Centre (spontaneous coronary artery dissection)* | None | None | None | None | None | None |
| Cynthia Arslanian-Engoren | University of Michigan School of Nursing | NIH/NINR: R21 (co-investigator [start date November 2017]; 5% for 1 year)† | None | None | None | None | None | University of Michigan School of Nursing† |
| Katherine E. Economy | Brigham and Women’s Hospital | None | None | None | None | None | None | None |
| Santhi K. Ganesh | University of Michigan | NIH†; Doris Duke Charitable Foundation† | None | None | None | None | None | None |
| Rajiv Gulati | Mayo Clinic | None | None | None | None | None | None | None |
| Mark E. Lindsay | Massachusetts General Hospital | None | None | None | None | None | None | None |
| Jennifer H. Mieres | Northwell Health | None | None | None | None | None | None | None |
| Sahar Naderi | Kaiser Permanente, Northern California | None | None | None | None | None | None | None |
| Svati Shah | Duke University Medicine DUMC | None | None | None | None | None | None | None |
| David E. Thaler | Tufts Medical Center | None | None | None | None | None | None | None |
| Marysia S. Tweet | Mayo Clinic | NIH (BIRCWH Scholar)† | None | None | None | None | None | None |
| Malissa J. Wood | Massachusetts General Hospital | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.